Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial

被引：36

作者：

Tsuboi, Hiroto ^{[1
]}

Matsumoto, Isao ^{[1
]}

Hagiwara, Shinya ^{[1
]}

Hirota, Tomoya ^{[1
]}

Takahashi, Hiroyuki ^{[1
]}

Ebe, Hiroshi ^{[1
]}

Yokosawa, Masahiro ^{[1
]}

Yagishita, Mizuki ^{[1
]}

Takahashi, Hidenori ^{[1
]}

Kurata, Izumi ^{[1
]}

Ohyama, Ayako ^{[1
]}

Honda, Fumika ^{[1
]}

Asashima, Hiromitsu ^{[1
]}

Miki, Haruka ^{[1
]}

Umeda, Naoto ^{[1
]}

Kondo, Yuya ^{[1
]}

Hirata, Shintaro ^{[2
]}

Saito, Kazuyoshi ^{[2
]}

Tanaka, Yoshiya ^{[2
]}

Horai, Yoshiro ^{[3
]}

Nakamura, Hideki ^{[3
]}

Kawakami, Atsushi ^{[3
]}

Sumida, Takayuki ^{[1
]}

机构：

[1] Univ Tsukuba, Dept Internal Med, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan

[2] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka, Japan

[3] Nagasaki Univ, Dept Immunol & Rheumatol, Unit Translat Med, Grad Sch Biomed Sci, Nagasaki, Japan

来源：

MODERN RHEUMATOLOGY | 2016年 / 26卷 / 06期

关键词：

Abatacept; Rheumatoid arthritis; Sjogren's syndrome; DOUBLE-BLIND; CLASSIFICATION CRITERIA; RITUXIMAB; BIOLOGICS; THERAPIES; DISEASE; CELLS;

D O I：

10.3109/14397595.2016.1158773

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To clarify the efficacy and safety of abatacept for secondary Sjogren's syndrome (SS) associated with rheumatoid arthritis (RA). Methods: The primary endpoint of this open-labeled, prospective, observational multicenter study for secondary SS with RA was the remission rate of Simplified Disease Activity Index (SDAI) at 52 weeks after initiation of abatacept. The secondary endpoints included Saxon's test and Schirmer's test. Adverse events and adherence rate during the study period were also analyzed. Results: Thirty-six patients (all females) were enrolled in this study. The mean SDAI decreased significantly from 20.6 +/- 11.2 (+/- SD) at baseline to 10.0 +/- 10.5 at 52 weeks (p<0.05). Patients with SDAI remission increased from 0 (0 week) to 12 patients (33.3%) at 52 weeks. Saliva volume assessed by Saxon's test increased significantly from 2136 +/- 1809 (0 week) to 2397 +/- 1878 (24 weeks) mg/2 min (n = 34, p<0.05). Saliva volume increased significantly from 2945 +/- 2090 (0 week) to 3419 +/- 2121 (24 weeks) mg/2 min in 11 patients with Greenspan grade 1 or 2 of labial salivary gland biopsy (p<0.05), but no change was noted in 18 patients with Greenspan grade 3 or 4. Tear volume by Schirmer's test increased significantly from 4.2 +/- 4.8 (0 week) to 6.4 +/- 7.8 (24 weeks) mm/5 min (n = 30, p<0.05). The adherence rate to abatacept was 80.6% (29/36) over the 52-week period. Twelve adverse events occurred in 10 of the 36 patients, and 7 of these events were infections. Conclusion: Abatacept seems to be effective for both RA and SS related manifestations.

引用

页码：891 / 899

页数：9

共 28 条

[1] Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjogren's Syndrome: A Pilot Study [J].

Adler, Sabine ;

Koerner, Meike ;

Foerger, Frauke ;

Huscher, Doerte ;

Caversaccio, Marco-Domenico ;

Villiger, Peter M. .

ARTHRITIS CARE & RESEARCH, 2013, 65 (11) :1862-1868

[2] 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].

Aletaha, Daniel ;

Neogi, Tuhina ;

Silman, Alan J. ;

Funovits, Julia ;

Felson, David T. ;

Bingham, Clifton O., III ;

Birnbaum, Neal S. ;

Burmester, Gerd R. ;

Bykerk, Vivian P. ;

Cohen, Marc D. ;

Combe, Bernard ;

Costenbader, Karen H. ;

Dougados, Maxime ;

Emery, Paul ;

Ferraccioli, Gianfranco ;

Hazes, Johanna M. W. ;

Hobbs, Kathryn ;

Huizinga, Tom W. J. ;

Kavanaugh, Arthur ;

Kay, Jonathan ;

Kvien, Tore K. ;

Laing, Timothy ;

Mease, Philip ;

Menard, Henri A. ;

Moreland, Larry W. ;

Naden, Raymond L. ;

Pincus, Theodore ;

Smolen, Josef S. ;

Stanislawska-Biernat, Ewa ;

Symmons, Deborah ;

Tak, Paul P. ;

Upchurch, Katherine S. ;

Vencovsky, Jiri ;

Wolfe, Frederick ;

Hawker, Gillian .

ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581

[3] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[4] Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study [J].

Dass, S. ;

Bowman, S. J. ;

Vital, E. M. ;

Ikeda, K. ;

Pease, C. T. ;

Hamburger, J. ;

Richards, A. ;

Rauz, S. ;

Emery, P. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1541-1544

[5] Treatment of Primary Sjogren Syndrome With Rituximab A Randomized Trial [J].

Devauchelle-Pensec, Valerie ;

Mariette, Xavier ;

Jousse-Joulin, Sandrine ;

Berthelot, Jean-Marie ;

Perdriger, Aleth ;

Puechal, Xavier ;

Le Guern, Veronique ;

Sibilia, Jean ;

Gottenberg, Jacques-Eric ;

Chiche, Laurent ;

Hachulla, Eric ;

Hatron, Pierre Yves ;

Goeb, Vincent ;

Hayem, Gilles ;

Morel, Jacques ;

Zarnitsky, Charles ;

Dubost, Jean Jacques ;

Pers, Jacques Olivier ;

Nowak, Emmanuel ;

Saraux, Alain .

ANNALS OF INTERNAL MEDICINE, 2014, 160 (04) :233-242

[6]

Fujibayashi Takashi, 2004, Mod Rheumatol, V14, P425, DOI 10.3109/s10165-004-0338-x

[7] Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis [J].

Guyot, Patricia ;

Taylor, Peter ;

Christensen, Robin ;

Pericleous, Louisa ;

Poncet, Coralie ;

Lebmeier, Maximilian ;

Drost, Pieter ;

Bergman, Gert .

ARTHRITIS RESEARCH & THERAPY, 2011, 13 (06)

[8] Characteristics of Sjogren's syndrome in rheumatoid arthritis [J].

He, Jing ;

Ding, Yan ;

Feng, Min ;

Guo, Jianping ;

Sun, Xiaolin ;

Zhao, Jing ;

Yu, Di ;

Li, Zhanguo .

RHEUMATOLOGY, 2013, 52 (06) :1084-1089

[9] Treating moderate to severe psoriasis - best use of biologics [J].

Lynch, Maeve ;

Kirby, Brian ;

Warren, Richard B. .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (02) :269-279

[10] Inefficacy of infliximab in primary Sjogren's syndrome -: Results of the randomized, controlled trial of Remicade in primary Sjogren's syndrome (TRIPSS) [J].

Mariette, X ;

Ravaud, P ;

Steinfeld, S ;

Baron, G ;

Goetz, J ;

Hachulla, E ;

Combe, B ;

Puéchal, X ;

Pennec, Y ;

Sauvezie, B ;

Perdriger, A ;

Hayem, G ;

Janin, A ;

Sibilia, J .

ARTHRITIS AND RHEUMATISM, 2004, 50 (04) :1270-1276

← 1 2 3 →